CENTENE CORP : Other Events (form 8-K)

December 13, 2019 at 05:25 pm EST

;"> WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 13, 2019

CENTENE CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware

001-31826

42-1406317

(State or Other Jurisdiction

Latest news about Centene Corporation

Molina Healthcare beats profit estimates aided by higher premiums	Apr. 24	RE
Wall St set for higher open as upbeat earnings obscure Mideast jitters	Apr. 16	RE
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15	MT
Top Midday Gainers	Apr. 15	MT
Sector Update: Health Care Stocks Gain Monday Afternoon	Apr. 15	MT
Sector Update: Health Care	Apr. 15	MT
Wells Fargo Raises Price Target on Centene to $93 From $89, Keeps Overweight Rating	Apr. 15	MT
Health Care Stocks Rise After Florida's Medicaid Contract Award Announcement	Apr. 15	MT
Sector Update: Health Care Stocks Decline Premarket Wednesday	Apr. 10	MT
Centene Says Meridian Unit Gets Michigan Medicaid Contracts	Apr. 09	MT
Centene Corporation Subsidiary Meridian in Michigan Receives Michigan Medicaid Contracts	Apr. 09	CI
Wells Fargo Lowers Price Target on Centene to $89 From $94, Maintains Overweight Rating	Apr. 08	MT
John Chevedden Files a Notice of Exempt Solicitation to Centene Corporation	Apr. 03	CI
US health insurers slide as final Medicare payment rates fall short of expectations	Apr. 02	RE
US health insurers slide as final Medicare Advantage rate sparks margin hit fears	Apr. 02	RE
The Vanguard Group, Inc. acquired 91-acre office campus of Centene Corporation for $117 million.	Apr. 01	CI
Centene Corporation Receives a Shareholder Proposal from John Chevedden	Mar. 28	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
North American Morning Briefing : Stocks Struggle -2-	Mar. 22	DJ
Stephens Downgrades Centene to Equal-Weight From Overweight, Cuts Price Target to $85 From $92	Mar. 21	MT
Wells Fargo Raises Centene's Price Target to $94 From $90, Maintains Overweight Rating	Mar. 20	MT
Transcript : Centene Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:00 AM	Mar. 12
Barclays Initiates Centene With Overweight Rating, Price Target is $101	Mar. 06	MT
Centene Insider Sold Shares Worth $774,100, According to a Recent SEC Filing	Feb. 16	MT
Centene Insider Sold Shares Worth $900,818, According to a Recent SEC Filing	Feb. 09	MT

Centene Corporation specializes in health services. Revenues break down by activity as follows: - development of health insurance programs (91%): primarily for children, pregnant women, blind and disabled persons; - specialized services (9%): pharmaceutical services (claims processing, pharmacy network management, mail order sales, home delivery, analysis and clinical consulting services, etc.), health care services by education and empowerment (behavioral orientation programs and welfare, nursing advice, etc.), eye and dental care services, home care services, development of health care management solutions, etc.

Sector

Managed Healthcare

Calendar

2024-04-26 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

INTERVIEW - Sarah London, CEO of Centene: How can we reduce healthcare costs?

June 27, 2023 at 04:45 pm EDT

More Strategies

Ratings for Centene Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

76.19 USD

Average target price

88.72 USD

Spread / Average Target

+16.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Managed Healthcare

	1st Jan change	Capi.
CENTENE CORPORATION	+2.67%	40.57B
UNITEDHEALTH GROUP INC.	-7.44%	447B
ELEVANCE HEALTH, INC.	+13.18%	124B
HUMANA INC.	-30.98%	39.54B
MOLINA HEALTHCARE, INC.	+1.69%	21.28B
PROGYNY, INC.	-12.32%	3.11B
ALIGNMENT HEALTHCARE, INC.	-39.84%	979M
CLOVER HEALTH INVESTMENTS, CORP.	-31.73%	312M